ONCY Oncolytics Biotech Inc.
$0.46▼ -2.30%
Healthcare
Other
After hours
$0.46▼ -0.04%
Oct 27, 4:57 PM ET
Volume 847.2K
Avg Volume (10D) 1.41M
Key Metrics & Fundamentals
Market Cap
$60.62M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.44 - 1.32
% vs 50 MA
-33.10%
% vs 200 MA
-46.98%
RSI-14
27.3
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.71
Free Cash Flow
-$8.14M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$9.37M
COGS
–
Operating Exp
$9.38M
Operating Income
-$9.38M
EBIT
-$9.38M
Pretax Income
-$9.34M
Net Income
-$9.44M
EPS (Diluted)
-0.08
Price & Volume History
Loading chart…
Recent News
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
GlobeNewswire · Oct 27, 2026 9:30 AM ET
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
GlobeNewswire · Oct 20, 2026 9:35 AM ET
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
GlobeNewswire · Oct 14, 2026 9:30 AM ET
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
CNW Group · Oct 14, 2026 4:07 AM ET
Oncolytics Biotech Details on Intellectual Property Strategy
MT Newswires · Oct 12, 2026 5:42 PM ET
Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
GlobeNewswire · Oct 12, 2026 4:05 PM ET
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
GlobeNewswire · Sep 29, 2026 9:30 AM ET
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
GlobeNewswire · Sep 28, 2026 9:30 AM ET
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
CNW Group · Sep 28, 2026 8:00 AM ET
3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets
Simply Wall St. · Sep 15, 2026 10:51 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ONCY's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.